Updated adult immunization schedule for ages 19 years or older released by CDC

The American College of Physicians, the CDC, the American Academy of Family Physicians, the American College of Nurse-Midwives, the American College of Obstetricians and Gynecologists, the Society for Healthcare Epidemiology of America, and the American Pharmacists Association have approved the immunization schedule.

Major changes to the adult immunization schedule for 2024 include the following:

Guidance has been revised to include the updated COVID-19 vaccines (2023-2024 formula).

Hepatitis A Vaccination

• The revised note clarifies that any individual who is not fully vaccinated and requests vaccination can receive hepatitis A vaccination.

Hepatitis B Vaccination

• Risk-based vaccination recommendations for individuals 60 years and older have been updated.
• A recommendation for shared clinical decision-making has been added for individuals 60 years and older with diabetes.

Human Papillomavirus (HPV) Vaccination

• Update to routine vaccination section: No additional doses are recommended for individuals who have completed the HPV vaccine series with any valency using the recommended dosing intervals.

Influenza Vaccination

· note has been added to the Special Situations section stating that persons with an egg allergy can receive any influenza vaccine (egg-based and non-egg-based) appropriate for age and health status.

Meningococcal Vaccination

· Menactra (MenACWY-D) has been removed from all sections.

· Penbraya (meningococcal groups A, B, C, W and Y vaccine) has been added to the schedule for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroups A, B, C, W, and Y in individuals 10 through 25 years of age.

Mpox Vaccination

· Guidance on the use of Jynneos (smallpox and monkeypox vaccine, live, nonreplicating) in adults based on sexual risk factors has been added.

Pneumococcal Vaccination

· Guidance on determining which pneumococcal vaccines a patient needs and the minimum intervals between doses has been revised to provide additional clarity.

Poliovirus Vaccination

· Routine recommendation updated to state that adults who are known or suspected to be unvaccinated or incompletely vaccinated should complete the 3-dose IPV primary series.

· Recommendations for adults who have completed the primary series and are at increased risk for exposure to poliovirus have been included.

Respiratory Syncytial Virus (RSV) Vaccination

· Information added on routine RSV vaccination during pregnancy; Abrysvo is the only RSV vaccine recommended for use during pregnancy.

· Guidance has been added on shared clinical decision-making for individuals aged 60 years or older; Arexvy or Abrysvo may be used.

· Guidance for providers in jurisdictions with RSV seasonality that differs from most of the continental US has been added.

· A note has been included listing the risk factors and medical conditions that increase a patient’s risk for severe RSV disease.

References:

Centers for Disease Control and Prevention. Adult Immunization Schedule by Age. Accessed November 17, 2023. https://www.cdc.gov/vaccines/schedules/hcp/imz/adult.html